Author Archives: donttradeourlivesaway

Gilead to brief US Congress on its pricing strategy for new oral Hep-C drug

US Congress demands briefing from Gilead on its pricing strategy for Sofosbuvir (Sovaldi)- new oral drug for Hep-C treatment for which it recently received marketing approval in US. The Committee of Energy and Commerce, House of Congress asked for providing … Continue reading

Posted in Drug Pricing, Hepatitis - C | Tagged , | Leave a comment

Recent developments on Hep-C treatment and access

Recently, there have been two key developments in the area of Hep-C treatment– firstly the release of the first ever WHO guidelines for screening, care and treatment of persons infected with HCV and secondly the specific discussion on generic production … Continue reading

Posted in Hepatitis - C, patent | Leave a comment

32 Members of US House of Representatives ask USTR to sanction Canada for not granting patents on drugs

Source: KEI Submitted by James Love,, 11. April 2014 A letter dated April 10, 2014 signed by a bipartisan group of 32 members of the House of Representatives, have asked USTR to elevate Canada to the Special 301 “priority watch list,” for “violation … Continue reading

Posted in USTR 301 report | Leave a comment

Eli Lilly vs. Canada: The Patent War Moves to Washington

Angered by Canadian court decisions that invalidated patents on two drugs, Eli Lilly is striking back by urging Washington to pressure Canada to change its stance toward intellectual property. Its efforts underscore growing frustration the pharmaceutical industry has toward some foreign governments … Continue reading

Posted in Investment treaties, investor state dispute, patent, USTR 301 report | Leave a comment

UK court overturns patents on Roche’s Herceptin

Source: Pharma Times 15 March 2014 The likelihood of a biosimilar version of Herceptin reaching the UK marketin the next few months has increased dramatically after the High Courtoverturned two key patents on Roche’s breast cancer blockbuster.The ruling, which stated … Continue reading

Posted in biosimilars, patent | Leave a comment

International Liver Conference: activists demand affordable hepatitis C treatment

Source: Hep Coalition 15 April 2014 International Liver Conference: activists demand affordable hepatitis C treatment Pills cost pennies, greed costs lives. As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise … Continue reading

Posted in access to medicines, Hepatitis - C | Leave a comment

Natco seeks to block Gilead’s hepatitis C drug patent in India: source

Source: Reuters 11 April 2014 (Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. … Continue reading

Posted in Generic drug, Hepatitis - C, patent, Patent Opposition | Tagged , , | Leave a comment

A matter of life and death

Source: Kashmir Times 11 April 2014 If you or some family members or friends suffer from cancer, hepatitis, AIDs, asthma or other serious ailments, it’s worth your while to follow the Trans-Pacific Partnership Agreement (TPPA) negotiations. It’s really a matter of … Continue reading

Posted in Compulsory Licensing, data exclusivity, TPPA, TRIPS plus | Leave a comment

Sun Pharma buys Ranbaxy to create generics giant

Source: Livemint 8 April 2014 Mumbai: Sun Pharmaceutical Industries Ltd, India’s biggest drug maker by market value, has agreed to acquire Ranbaxy Laboratories Ltd, controlled by Japan’s Daiichi Sankyo Co. Ltd, in an all-stock deal worth $3.2 billion that will … Continue reading

Posted in Generic drug, Other | Leave a comment

Merger with Sun Pharma will spell the end of Ranbaxy brand, but a new dawn beckons

Source: The Economic Times 8 April 2014 This writer had received some phone calls last Sunday from the media whether one could confirm if Sun Pharma was indeed buying up Ranbaxy Laboratories. Can anybody keep such a possibility completely under … Continue reading

Posted in Other | Leave a comment